We and the other groups demonstrated that CD133 triggers the activation of PI3K/AKT pathway and potentiates oncogenic ability of glioma, hepatocellular carcinoma, neuroblastoma and colon cancer cells [145,146,147]. Here, PROM1 is linked to glioma.